QIAGEN NV to acquire Cellesis Limited
QIAGEN NV has reached an agreement to acquire Cellestis Limited for approximately AU$341 million in cash, providing QIAGEN with access to a novel ‘pre-molecular’ technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.
The acquisition of Cellestis will provide QIAGEN with exclusive rights to QuantiFERON technology, a proprietary approach for disease detection and monitoring.
QuantiFERON is complementary to QIAGEN’s portfolio of molecular diagnostics. Its high sensitivity and ability to provide clinically relevant information means that this technology can be used ahead of DNA- or RNA-based molecular testing. Greater use of QuantiFERON technology can help guide and drive the use of traditional DNA- and RNA-based molecular diagnostics.
Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO
To lead the commercialisation of Vaxxas's proprietary high‑density microarray patch (HD‑MAP)...
Optics11 Life appoints Jacquelien ten Dam as CEO
Optics11 Life plans to accelerate its commercial growth in key markets while building strategic...
Epilepsy pioneer elected President of Aust Academy of Science
Laureate Professor Sam Berkovic — one of the world's most respected neurologists...
